Monthly average number of migraine days with and without MO
The placebo-adjusted LS mean (95% CI) reduction from baseline in monthly average number of migraine days in patients with MO at baseline was significantly greater with fremanezumab quarterly (− 2.0 [− 3.1 to − 1.0], P = 0.0002) and monthly (− 2.4 [− 3.5 to − 1.4], P < 0.0001) (Fig. 1b). Similar results were seen in patients without MO at baseline (quarterly − 1.4 [− 2.5 to − 0.3], P = 0.0132; monthly − 1.3 [− 2.4 to − 0.2], P = 0.0249 vs placebo]) (Fig. 1b). Numerically greater reductions in monthly average number of migraine days from baseline and a larger treatment difference over placebo were seen in fremanezumab-treated patients with MO compared with patients without MO.